Baird draws positive reads from early optimism in health system CFO survey
Baird's survey of health systems CFOs (80 of them, representing about $76B in annual revenue and about 84,000 licensed inpatient beds) points to a somewhat upbeat mood for 2021. Comps
Seekingalpha · 11/18 23:39
Stock Market Rally At Highs, But Who Will Lead? Google, Microsoft, Visa,, Moderna Coronavirus Vaccine In Focus
Investor's Business Daily · 11/14 16:49
Wild Ride For Illumina Stock Shows Promise, Challenge Of Multi-Cancer Blood Tests
Investor's Business Daily · 11/13 13:30
Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings
Zacks · 11/02 15:45
Exact Sciences Corporation 2020 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Exact Sciences Corporation in conjunction with their 2020 Q3 earnings call.
Seekingalpha · 10/29 23:36
Citigroup Downgrades Exact Sciences to Neutral, Raises Price Target to $140
Citigroup analyst Patrick Donnelly downgrades Exact Sciences (NASDAQ:EXAS) from Buy to Neutral and raises the price target from $120 to $140.
Benzinga · 10/28 12:19
BofA sees 11% upside in Exact Sciences after liquid biopsy move
Bank of America Global Research maintains its Buy rating on Exact Sciences (EXAS) after it announced its planned acquisition of liquid biopsy developer Thrive Earlier Detection Corp. for $2.15B in
Seekingalpha · 10/28 12:09
Exact Sciences Highlights US Preventive Services Task Force Draft Updated Guidelines For Colorectal Cancer Screening To Begin At Age Of 45, Including Co.'s Cologuard
The United States Preventive Services Task Force (USPSTF) today released draft updated colorectal cancer screening guidelines recommending that screening begin at age 45, and including Exact Sciences'
Benzinga · 10/27 20:43
NGL, EXAS, HOG and KALA among midday movers
Gainers: Scholar Rock (SRRK) +87%.Weidai (WEI) +60%.1847 Goedeker (GOED) +43%.Harley-Davidson (HOG) +27%.Synalloy (SYNL) +25%.Exact Sciences (EXAS) +22%.Harbor Custom Development (HCDI) +21%.TuanChe (TC) +20%.Unifi (UFI) +19%.CASI Pharmaceuticals (CASI) +18%.Losers: Catabasis Pharmaceuticals (CATB) -70%.Liquid Media Group (YVR) -21%.Knoll
Seekingalpha · 10/27 16:43
Sell-siders weigh in on Exact Sciences after Q3 report, announced acquisitions
Sell-side analysts opine on Exact Sciences ([[EXAS]] +19.5%) after its Q3 revenue beat and announced acquisitions of two developers of screening tests for the early detection of cancer.Stifel's Daniel Arias
Seekingalpha · 10/27 16:18
Scholar Rock, Exact Sciences leads healthcare gainers; Catabasis Pharmaceuticals, Galera Therapeutics among major losers
Gainers: Scholar Rock Holding (SRRK) +80%, Exact Sciences (EXAS) +18%, CHF Solutions (CHFS) +17%, CASI Pharmaceuticals (CASI) +13%, Prelude Therapeutics (PRLD) +8%.Losers: Catabasis Pharmaceuticals (CATB) -68%, Galera Therapeutics (GRTX) -14%, Genfit (GNFT) -13%, Kala Pharmaceuticals (KALA) -9%, GeoVax Labs (GOVX) -7%.
Seekingalpha · 10/27 15:02
Exact Sciences Q3 top-line up 87%; non-GAAP gross margin of 77%
Exact Sciences ([[EXAS]]) Q3 results:Revenues: $408.4M (+86.7%); Screening revenue was $214.6M, -2% Y/Y.Precision Oncology revenue: $91.6M; COVID-19 testing revenue was $102.2M.GAAP Gross margin of 72%, non-GAAP gross margin was 77%.Net
Seekingalpha · 10/27 13:13
AIG, HSBC, XLNX and EXAS among premarket gainers
1847 Goedeker (GOED) +81% on announcing agreement for the acquisition of Appliances Connection.SPI Energy (SPI) +40%.Sunworks (SUNW) +17%.Xilinx (XLNX) +13% as AMD to acquire the company in an all-stock transaction valued at $35B.Neptune Wellness
Seekingalpha · 10/27 12:21
Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering
Exact Sciences Corporation (Nasdaq: EXAS) today announced the entry into agreements to sell an aggregate of 8,605,483 shares (the "Shares") of its common stock, par value $0.01 per share, in a registered direct offering to ten institutional investors, including some of its largest shareholders as well as healthcare specialist firms Casdin Capital and Rock Springs Capital.
PR Newswire · 10/27 12:10
Exact Sciences Announces Third Quarter 2020 Results
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.
PR Newswire · 10/27 12:01
Exact Sciences Buys Thrive for $2.5 Billion in Cash and Stock
Blood-screening company Exact Sciences agrees to buy privately held cancer-detection provider Thrive Earlier Detection for $2.5 billion in cash and stock. · 10/27 11:45
Exact Sciences expands into early cancer detection with two acquisitions
Expanding its footprint in cancer testing, Exact Sciences (EXAS) has agreed to acquire Baltimore, MD-based Thrive Earlier Detection Corp. for up to $2.15B in cash and stock. The transaction should
Seekingalpha · 10/27 11:37
Exact Sciences to sell $869M of common stock in registered direct offering
Exact Sciences (EXAS) -3% to sell an aggregate of 8.6M common shares in a registered direct offering to ten institutional investors at $101/share for gross proceeds of ~$869.2M and net proceeds of ~$866M.Institutional
Seekingalpha · 10/27 11:21
Exact Sciences raising $869M to fund cancer detection acquisitions
Exact Sciences (EXAS) to sell an aggregate of 8.6M common shares in a registered direct offering to ten institutional investors at $101/share, for gross proceeds of ~$869.2M and net proceeds
Seekingalpha · 10/27 11:21
Exact Sciences to acquire Thrive Earlier Detection Corp. in cash and stock deal worth up to $2.15 billion
Exact Sciences Corp. undefined said Tuesday it has agreed to acquire Thrive Earlier Detection Corp. in a cash and stock deal worth up to $2.15 billion....
MarketWatch · 10/27 11:14
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about EXACT Sci through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.